These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30914533)

  • 21. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
    Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
    Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.
    Baldi GG; Di Donato S; Fargnoli R; Dona M; Bertulli R; Parisi E; Fantini L; Sbaraglia M; Panella M
    Anticancer Drugs; 2016 Oct; 27(9):908-13. PubMed ID: 27348763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
    Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
    Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of trabectedin for the treatment of liposarcoma.
    Zijoo R; von Mehren M
    Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
    Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Bompas E; Alexandre J; Collard O; Lebrun-Ly V; Soulier P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    ESMO Open; 2021 Aug; 6(4):100209. PubMed ID: 34325109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.
    Stoyianni A; Kapodistrias N; Kampletsas E; Pentheroudakis G; Pavlidis N
    Tumori; 2011; 97(2):252-5. PubMed ID: 21617727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Adam JP; Boumedien F; Letarte N; Provencher D
    Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
    Morioka H; Takahashi S; Araki N; Sugiura H; Ueda T; Takahashi M; Yonemoto T; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Susa M; Nakayama R; Nishimoto K; Kikuta K; Horiuchi K; Kawai A
    BMC Cancer; 2016 Jul; 16():479. PubMed ID: 27418251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
    Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
    Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
    Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
    Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.
    Aliberti S; Miano S; Tolomeo F; Merlini A; Aglietta M; Grignani G
    Future Oncol; 2020 Jan; 16(1s):15-19. PubMed ID: 31916842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
    Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
    Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.